A phase III, multi-center, randomized, double blind, active and placebo control, single dose trial to demonstrate the efficacy and safety of DWP-450 in adult subjects for treatment of moderate-to-severe glabellar lines

Trial Profile

A phase III, multi-center, randomized, double blind, active and placebo control, single dose trial to demonstrate the efficacy and safety of DWP-450 in adult subjects for treatment of moderate-to-severe glabellar lines

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Apr 2018

At a glance

  • Drugs Botulinum-Toxin-A (Primary)
  • Indications Glabellar lines
  • Focus Registrational; Therapeutic Use
  • Acronyms EV003
  • Sponsors Evolus
  • Most Recent Events

    • 05 Apr 2018 According to an Evolus media release, Dr. Patricia Ogilvie, M.D., is the Principal Investigator of the study. A Biologics License Application (BLA) for prabotulinumtoxinA is currently under review by the U.S. FDA.
    • 05 Apr 2018 Results presented in the Evolus media release.
    • 05 Apr 2018 Results from this trial were presented at the Aesthetic & Anti-Aging Medicine World Congress (AMWC) (2018), according to an Evolus media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top